TSN-084 is under clinical development by Tyligand Biotechnology (Shanghai) and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TSN-084’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TSN-084 is under development for the treatment of advanced malignant tumors, solid tumors. The drug candidate is administered through oral route in the form of tablets and acts by targeting CDK8/19.
Tyligand Biotechnology (Shanghai) overview
Tyligand Biotechnology (Shanghai) (Tyligand Biotechnology) is a drug research and development company. Tyligand Biotechnology is headquartered in Shanghai, China.
For a complete picture of TSN-084’s drug-specific PTSR and LoA scores, buy the report here.